Evidence map›Paper›PMID 28708130›Full record

ArticleBlood cancer journal2017

Clinical and prognostic significance of e1a2 BCR-ABL1 transcript subtype in chronic myeloid leukemia.

Z Gong, L J Medeiros, J E Cortes, L Zheng, J D Khoury, W Wang, G Tang, S Loghavi, R Luthra, W Yang and 2 more

Abstract readLetter
In one paragraph

Article in Blood cancer journal, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Guideline
  2. Pooled it
  3. Article
  4. Review
  5. Review
  6. Article
  7. Development of a Multiplex PCR to Detect theCancer management and research · 2026
    Article
  8. The silent players: AtypicalOncology reports · 2025
    Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Non-Coding RNAs Are Implicit in Chronic Myeloid Leukemia Therapy Resistance.International journal of molecular sciences · 2022
    Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. A case of e1a2 (minor, P190)Blood research · 2021
    Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Z GongDepartments of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
L J MedeirosDepartments of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
J E CortesDepartments of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
L ZhengDepartments of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
J D KhouryDepartments of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
W WangDepartments of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
G TangDepartments of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
S LoghaviDepartments of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
R LuthraDepartments of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
W YangDepartment of Hematology, Shengjing Hospital of China Medical University, Shenyang, China.
H M KantarjianDepartments of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
S HuDepartments of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AdolescentAdultAftercareAgedAged, 80 and overDisease-Free SurvivalFemaleFusion Proteins, bcr-ablHumansLeukemia, Myelogenous, Chronic, BCR-ABL PositiveMaleMiddle AgedSurvival RateBCR-ABL1 fusion protein, humanFusion Proteins, bcr-abl

Identifiers

PMID28708130
PMCPMC5549254

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.